Yahoo! Deal Kicks O...
Health Care: Drugs
Keryx Biopharmaceuticals Inc. (KERX: NASDAQ)
$8.13 0.09 | 1.12%
05/20/13 - 11:10 AM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 14.68M | 35.25M | 28.41M | 16.39M |
| Receivables | 0.00 | 7.00K | 0.00 | 66.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 430.00K | 534.00K | 200.00K | 1.52M |
| Total Current Assets | 15.11M | 40.00M | 28.71M | 35.52M |
| Property, Plant & Equipment, Gross | 879.00K | 855.00K | 798.00K | 775.00K |
| Accumulated Depreciation & Depletion | 823.00K | 788.00K | 741.00K | 681.00K |
| Property, Plant & Equipment, Net | 56.00K | 67.00K | 57.00K | 94.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 198.00K | 209.00K | 137.00K | 2.00M |
| Total Non-Current Assets | 3.46M | 3.48M | 3.40M | 5.30M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 18.57M | 43.49M | 32.11M | 40.82M |
| Accounts Payable | 7.21M | 8.87M | 5.37M | 5.00M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 120.00K |
| Total Current Liabilities | 8.04M | 9.77M | 6.19M | 6.03M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 36.00K | 2.67M | 2.67M | 2.69M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 36.00K | 2.67M | 2.67M | 2.69M |
| Total Liabilities | 8.08M | 12.44M | 8.87M | 8.72M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 10.49M | 31.05M | 23.25M | 32.10M |
| Common Par | 72.00K | 71.00K | 62.00K | 57.00K |
| Additional Paid In Capital | 403.39M | 401.22M | 365.31M | 353.65M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -392.61M | -369.89M | -341.76M | -321.43M |
| Treasury Stock | -357.00K | -357.00K | -357.00K | -357.00K |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 180.00K |
| Total Capitalization | 10.49M | 31.05M | 23.25M | 32.10M |
| Total Equity | 10.49M | 31.05M | 23.25M | 32.10M |
| Total Liabilities & Stock Equity | 18.57M | 43.49M | 32.11M | 40.82M |
| Total Common Shares Outstanding | 71.92M | 71.02M | 61.44M | 56.48M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 79.95K | 79.95K | 79.95K | 79.95K |
| Basic Weighted Shares Outstanding | 71.63M | 67.37M | 58.99M | 49.94M |
| Diluted Weighted Shares Outstanding | 71.63M | 67.37M | 58.99M | 50.50M |
| Number of Employees | 25 | 29 | 25 | 15 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with KERX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserBio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- User1st Time out
Latest KERX Headlines from TheStreet
- Today's Drugs Industry Featured Laggard: Keryx Biopharmaceuticals Inc. (KERX) 04.11.13 | 05:04 pm
- Bears Eat Herbalife, JC Penney - Bulls Find Keryx
04.09.13 | 12:04 pm - Keryx Biopharmaceuticals Inc. (KERX): Health Care's Highlighted Dud Of The Day 03.26.13 | 05:03 pm
- Keryx CEO vs. A Short Seller: Zerenex Patent Debate 03.13.13 | 07:03 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 03.08.13 | 07:03 pm
- Why Expect More Price Swings From These 4 Biotechs 02.28.13 | 11:02 am
- Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Drugs Laggard 02.27.13 | 05:02 pm
- Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Health Care Winner 02.12.13 | 05:02 pm
- 3 Biotech Stocks Under $10 Moving Higher 02.12.13 | 02:02 pm
- Ziopharm's Sarcoma Study And The Feuerstein-Ratain Rule 02.05.13 | 06:02 am
Press Releases for KERX
- Keryx Biopharmaceuticals, Inc. To Host Conference Call On First Quarter 2013 Financial Results - PR Newswire 05.06.13 | 04:05 pm
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - Business Wire 03.25.13 | 08:03 am
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - PR Newswire 03.19.13 | 06:03 pm
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - Business Wire 03.18.13 | 05:03 pm
- Keryx Biopharmaceuticals To Present At The 25th Annual ROTH Conference - PR Newswire 03.14.13 | 08:03 am
- Keryx Biopharmaceuticals Announces Appointment Of Amit Sharma, M.D. As Vice President, Medical Affairs - PR Newswire 03.13.13 | 08:03 am
- Keryx Biopharmaceuticals, Inc. To Host Conference Call On Fourth Quarter And Year-End 2012 Financial Results - PR Newswire 03.11.13 | 08:03 am
- Keryx Biopharmaceuticals To Present At The Citigroup 2013 Global Healthcare Conference - PR Newswire 02.22.13 | 08:02 am
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact The Firm - PR Newswire 02.08.13 | 09:02 pm
- Harwood Feffer LLP Announces Investigation Of Keryx Biopharmaceuticals, Inc. - PR Newswire 02.08.13 | 12:02 pm
Partner Headlines for KERX
- Zerenex Phase III Data Imminent; Odds Still High For Keryx To Succeed With This Drug - Seeking Alpha 01.22.13 | 09:01 am
- Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals - Benzinga 11.28.12 | 09:11 am
- Healthcare Biz Roundup: Keryx Jumps Without CAUSE, Teva Not A MONOPOLIST - Wall St. Cheat Sheet 07.04.12 | 08:07 am
- Zacks' Voice of the People highlights opportunities with Starbucks, Realty Income, Keryx Biopharma, Bon-Ton Stores and Orexigen Therapeutics - Press Releases - Zacks 04.12.12 | 09:04 am
- 2 Biotech Stocks To Consider Now, 1 To Avoid - Seeking Alpha 04.10.12 | 09:04 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- VIX - Options Volatility Sonar: Friday Recap - Seeking Alpha 03.16.12 | 05:03 pm
- Morning Social Media Outlook for Tuesday Mar 6 (SHFL, HAR, PCX, NTRI) - Benzinga 03.06.12 | 09:03 am
- FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris - Seeking Alpha 03.02.12 | 05:03 pm
- 3 Boring Dividend Stocks You Will Grow To Love - Seeking Alpha 02.26.12 | 07:02 am
